|
July 2010
XVIII IAC Citations
|
-
A WEEK-IN-REVIEW
FEATURED REPORT
POSTER
Switching from Kivexa [ABC/3TC ]+Kaletra
[LPV/r] to Truvada [TDF/FTC]+Kaletra [LPV/r] reduces
high cholesterol: results of a 12 week randomized, controlled study (ROCKET II)
G. Behrens, R. Maserati, A. Rieger, et al
PDF Poster
Abstract
-
POSTER
Safety and adherence to intermittent emtricitabine/tenofovir for HIV
pre-exposure prophylaxis (PrEP) |
in Kenya and Uganda
G. Mutua, E.J. Sanders, A. Kamali, et al
PDF Poster
Abstract
-
POSTER
The partners PrEP study: enrollment of HIV-1 serodiscordant
couples into a phase III, randomized
trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention
J. Baeten, N. Mugo, P. Ndase, et al
PDF Poster
Abstract
-
Exposure of extracellular and intracellular tenofovir and emtricitabine in
mucosal tissues after a single
of fixed-dose TDF/FTC: implications for pre-exposure HIV prophylaxis (PrEP)
K. Patterson, H. Prince, E. Kraft, et al
- Incidence
of emtricitabine, tenofovir, raltegravir, and lopinavir resistance following
twice-daily (BID)
lopinavir/ritonavir (LPV/r) in combination with once-daily (QD)
emtricitabine/tenofovir (FTC/TDF) or
twice daily raltegravir (RAL) in antiretroviral-naïve, HIV-1 infected subjects:
48-week results of a 96-week
randomized trial (study M10-336)
A. Lawal, L. Maroldo, R. Rivero, et al
-
Virological response to atazanavir, ritonavir and tenofovir/emtricitabine:
relation to individual
pharmacokinetic parameters and adherence measured by medication events
monitoring system (MEMS)
in naïve HIV-infected patients (ANRS134 trial)
C. Goujard, A. Barrail-Tran, X. Duval, et al
-
Bioequivalence of the co-formulation of
emtricitabine/rilpivirine/tenofovir DF
A. Mathias, M. Menning, X. Wei, et al
|
| Journal Citations |
|
|
|
|
|
|
|
Tenofovir Main Page
US
Treatment Guidelines
